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ulcers; increased age; multiple NSAID use; high NSAID dose; 
concomitant use of corticosteroids or anticoagulants including 
acetylsalicylic acid
6); concomitant Helicobactor pylori (H. pylori) 
infection
7,8); comorbidities, such as significant cardiovascular 
disease; female gender9; and severe rheumatoid arthritis.
  Most global and domestic guidelines for clinical practitioners 
recommend the use of either a cyclooxygenase-2 (COX-2) 
selective agent or a nonselective NSAID with co-prescription of 
gastroprotective agents in patients with the risk factors
3-5).
  The aim of this study was to describe the patterns of use 
of NSAIDs for arthritic knees in clinical practice in Korea, 
particularly focusing on the co-prescription of gastroprotective 
agents for patients with or without the risk factors for GI toxicity 
or adverse GI events.
Materials and Methods
  A survey was performed in the ambulatory of 82 hospitals 
(62 university and 20 general hospitals) where 111 physicians, 
members of the Korean Knee Society, had prescribed NSAIDs to 
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Purpose: Th   e aim of this study was to describe the patterns of use of non-steroidal anti-infl  ammatory drugs (NSAIDs) for arthritic knees in clinical 
practice, particularly focusing on the co-prescription of gastroprotective agents for patients with risk factors for adverse gastrointestinal (GI) events.
Materials and Methods: Each cross-sectional cohort was a group of outpatients visiting 111 physicians who had prescribed NSAIDs for the patients’ 
arthritic knees for more than three consecutive months. A self-administered questionnaire was completed by each patient and physician.
Results: Nine hundred and forty fi  ve patients (48%) of the whole 1,960 patients belonged to the group with a high or very high risk for NSAID-
induced gastropathy determined by northern California Health Maintenance Organization guidelines. Overall, only less than half of the patients were 
given co-prescription of gastroprotective agents, regardless of the presence or absence of GI symptoms and irrespective of the level of risk for NSAID-
induced gastropathy.
Conclusions: Th   e physician prescribing NSAIDs for arthritic knees should monitor any GI symptoms and the patient monitor anylevel for NSAID-
induced gastropathy, and be willing to add gastroprotective agents as necessary in order to prevent serious adverse GI events.
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Introduction
  Risk factors for development of gastrointestinal (GI) toxicity 
in patients receiving non-steroidal anti-inflammatory drugs 
(NSAIDs) for arthritis or other musculoskeletal diseases 
include
1-5) prior history of complicated or uncomplicated 
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relieve symptoms and signs of arthritic knees for more than three 
consecutive months. Th   is cross-sectional observational study was 
performed on a single day between August and October 2009, 
although the exact date of study was diff  erent among the survey 
sites. 
  All the patients were ≥20 years old, had been taking oral 
NSAIDs for more than three consecutive months, and required 
additional prescription of NSAIDs for symptomatic relief of their 
arthritic knees. A self-administered questionnaire was completed 
by each of the 2,000 patients who fulfilled those inclusion 
criteria and by the physicians to get the information of the recent 
and current prescriptions. The questionnaire for the patient 
included questions on the risk factors for GI adverse effects, 
such as age, gender, general condition, any history of peptic 
ulcer with or without hemorrhage or perforation, concomitant 
use of anticoagulants or corticosteroids, concomitant H. pylori 
infection, and comorbidities, such as significant cardiovascular 
disease. It also included questions about the status of the aff  ected 
knee joint and any adverse GI symptoms. The data from the 
questionnaires filled up by the physicians were analyzed to 
investigate the prescribing habits of NSAIDs and gastroprotective 
agents and to determine whether the physicians took any GI 
symptoms and the patient’s own risk level into consideration 
when they prescribed medicine.
  Th   e patients were stratifi  ed according to the risk of developing 
adverse GI events by using the Standardized Calculator of Risk 
for Events (SCORE) tool. The SCORE had been developed at 
Stanford University
1) and become the base of the treatment 
guidelines for the use of NSAIDs that was disseminated by 
northern California Health Maintenance Organization (HMO). 
Th   e SCORE tool assigned points for six patient factors including 
age, gender, morbidity, GI problems, and rheumatoid. Whereas 
the HMO classifi  cation categorized patients as level 1 or lowest 
risk (1-15 points), level 2 or intermediate risk (16-20 points), 
and level 3 risk (21 points or greater)
9) we classifi  ed the patients 
into low risk (1-10 points), moderate risk (11-15 points), high 
risk (16-20 points), and very high risk (21 points or greater) of 
developing serious GI complications.
Results
  Of the 2,000 patients who completed the questionnaire, 1,960 
met the eligibility criteria based on the rules for inclusion and 
exclusion. Fifty-six per cent of the subjects were more than 65 
years of age and 76% were female.
  Table 1 presents the prevalence of individual risk factor for GI 
complications. One hundred and sixty patients (8%) were at very 
high GI risk, and 785 patients (40%) were considered at high risk 
for adverse GI events (Table 2). 
  Among the patients in a high or very high risk group, 321 
patients (34%) had a prescription of COX-2 inhibitors, 331 
patients (35%) nonselective NSAIDs without co-prescription 
of gastroprotective agents, and 293 patients (31%) nonselective 
NSAIDs plus gastroprotective agents (Table 3). This means, 
among 542 high or very high-risk patients taking NSAIDs 
without the co-prescription of gastroprotective agents, 331 
patients (61%) were given non-selective NSAIDs instead 
Table 1. Th   e Prevalence of Risk Factors for Gastrointestinal (GI) Toxicity 
(n=1,960) 
Risk factors No. of cases (%)
Age ≥ 65 years 1,095 (56)
Prior history GI adverse events    784 (40)
Comorbidities    490 (25)
Concomitant use of corticosteroids     275 (14)
Rheumatoid arthritis     197 (10)
Concomitant use of aspirin    117 (6)
Concomitant use of anticoagulant      39 (2)
Prior history of admission for serious GI adverse 
events
     39 (2)
Poor general condition      20 (1)
Percentage total more than 100% because of concurrent risk factors.
Table 2. Patients Stratified by Risk of Developing Gastrointestinal 
Complications using SCORE Tool (n=1,960)
Risk level (level determined by HMO guideline
9)) No. of cases (%)
Very high > 21 points (level 3) 160 (8) 
High 16-20 points (level 2)   785 (40)
Moderate 11-15 points (level 1)   784 (40)
Low < 11 points (level 1)    231 (12)
SCORE: standardized calculator of risk for events, HMO: health 
maintenance organization. 
Table 3. NSAID Prescribed in Patients with High or Very High Risk for 
GI Toxicity (n=945)
NSAIDs prescribed No. of cases (%)
Coxibs without gastroprotective agents 211 (22)
Coxibs with gastroprotective agents 110 (12)
Non-selective NSAIDs without gastroprotective agents 331 (35)
Non-selective NSAIDs with gastroprotective agents 293 (31)
NSAID: non-steroidal anti-inflammatory drug, GI: gastrointestinal, 
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of selective NSAIDs. Whether the patients had adverse GI 
symptoms or not did not aff  ect the proportion of patients taking 
selective NSAIDs (Table 4).
  Overall, a gastroprotective therapy was performed in 805 (41%) 
patients and only less than half of the patients were given co-
prescription of gastroprotective agents regardless of the presence 
or absence of GI symptoms and irrespective of the level of risk for 
NSAID-induced gastropathy (Table 5). Among the patients using 
the preventive drugs, 255 (32%) patients received rebamipide 
whereas histamine2 (H2)-receptor antagonists (H2RA) were 
coprescribed for 191 (24%) patients (Table 6).
Discussion
  Th   e most frequent and signifi  cant adverse eff  ect associated with 
NSAIDs is GI toxicity. Th   e symptoms of GI toxicity include both 
annoying maladies, such as dyspepsia or disgust, and serious 
events, such as GI ulcers with hemorrhage or perforation. 
  Despite all global and domestic guidelines recommending the 
use of either a COX-2 inhibitor or a nonselective NSAID with 
co-prescription of gastroprotective agents for patients who are 
at risk of developing GI toxicity, almost thirty-five per cent of 
the patients at high or very high risk took nonselective NSAIDs 
without co-prescription of gastroprotective agents in this study. 
Besides, more than half of the patients complaining of GI 
symptoms were not given co-prescription of gastroprotective 
agents, and only a quarter of the patients complaining of GI 
symptoms were given prescription of selective COX-2 inhibitors 
in this study. 
  Overall, only less than half of the patients were given co-
prescription of gastroprotective agents regardless of the presence 
or absence of GI symptoms and irrespective of the level of risk 
for NSAID-induced gastropathy. There have been disparities 
between medication guidelines and government’s reimbursement 
policies which may modify the enthusiasm of some practitioners 
for gastroprotection. 
  With regard to gastroprotective agents, proton pump inhibitor 
(PPI) or misoprostol has been widely recognized as the most 
effective one
10). PPIs including omeprazole, lansoprazole
11), 
and esomeprazole
12) significantly reduced symptomatic ulcers 
among patients receiving NSAIDs. However, one must also 
consider potential complications of the long-term PPI use 
including acceleration of corpus atrophy and, possibly, its role 
in hip fractures, pneumonia, and pseudomembranous colitis
8). 
It has been shown that the incidence of peptic ulcers associated 
with NSAID use can be reduced by cotherapy with the synthetic 
prostaglandin misoprostol. However, poor tolerability is a major 
limitation of the drug. In a clinical trial
13), 27.5% of misoprostol-
treated patients withdrew prematurely from the study due to 
adverse events, most of which were GI complaints including 
abdominal pain and diarrhea.
  Although most global and domestic guidelines recommend 
the use of PPI or misoprostol for gastroprotection
3-5), other 
Table 4. Utilization of Coxibs in Patients with or without GI Risks or 
Symptoms
Patients taking NSAIDs  Coxibs
High or very high risk group (n=945) 321 (34)
Moderate or low risk group (n=1,015)  162 (16) 
With GI symptoms (n=941)  223 (24)
No GI symptoms (n=1,019)  260 (26)
Values are presented as number (%).
NSAID: non-steroidal anti-inflammatory drug, GI: gastrointestinal, 
Coxibs: cyclooxygenase-2 selective NSAIDs.
Table 6. Types of Gastroprotective Th  erapy  (n=805)
Gastroprotective agents  No. of patients (%) 
Cytoprotectant 347  (43) 
Rebamipide 255 (32)
Ecabet sodium granules  24 (3)
H2RA 191 (24)
Rranitidine 105  (13)
Cimetidine 23 (3)
Gastroprokinetics 107 (13)
Levosulpride 27 (3)
Mosapride 25 (3)
Itopride 24 (3)
Domperidone 23 (3)
PPI 71 (9)
Pantoprazole 42 (5)
Others 268  (33)
Percentage total more than 100% because of concomitant use.
H2RA: histamine2-receptor antagonist, PPI: proton pump inhibitor.
Table 5. Prevalence of Use of Gastroprotective Agents in Patients Taking 
Non-steroidal Anti-infl  ammatory Drugs (NSAIDs)
Patients taking NSAIDs  Gastroprotection 
High or very high risk group (n=945)  406 (43)
Moderate or low risk group (n=1,015)  399 (39)
With GI symptoms (n=941)  412 (44)
No GI symptoms (n=1,019)  393 (39)
Values are presented as number (%).206    Kim et al. Oral NSAIDs with or without Co-prescription of Gastroprotective Agent
options that might reduce the risk for NSAID-related upper GI 
complications are also available. Symptomatic low risk patients 
without evidence of blood loss may switch to another NSAID (or 
coxib) or receive treatment with antacids or H2RA
10).
  Selective COX-2 inhibitors (coxibs) are safer to the GI tract 
than traditional NSAIDs. However, current prevention strategies 
for patients who need NSAIDs should also take into account 
the presence of cardiovascular (CV) risk factors, as coxibs and 
probably post traditional NSAIDs increase the incidence of 
serious CV events
2). Moreover, the introduction of coxibs has not 
completely eliminated GI adverse events. Th   ere have been several 
reports that COX-2-inhibitor users did not have a reduced 
risk of a GI bleed compared with patients using nonselective 
NSAIDs
14). Currently, it is accepted that the choice of an NSAID 
should be determined by the need to balance each patient’s GI 
and CV risks. Several trials with less potent COX-1 inhibitors 
showed significant reductions in endoscopic gastric ulcers and 
erosions
10,15,16). The development of COX-2-selective inhibitors 
and the formation of other new, safer inhibitors should broaden 
the range of options. 
  Although acid inhibitors may relieve symptoms, they have 
not been proven to reduce GI complications, Among H2RA, 
only high dose of famotidine has been recognized as a 
gastroprotective agent in most official guidelines. Recent 
improvements in the understanding of NSAID-induced damage 
and new gastroprotective agent development
17) would provide 
an opportunity for eff  ective anti-infl  ammatory with reduced GI 
complications.
  In summary, strategies for reducing the risk for NSAID-related 
GI complications remain underused even in high-risk patients 
and patients with GI symptoms. Th   us, the physician prescribing 
NSAIDS for arthritic knees should determine the level of 
patient’s own risk for NSAID-induced gastropathy, monitor 
any developing GI symptoms, and be willing to prescribe 
gastroprotective agents for the patient, in order to prevent 
serious adverse events. Also, the ultimate choice of therapy for 
a particular patient depends on several things including risk 
factors, the preferences of the patient and the physician, and 
cost
10). 
Conclusions
  The physician prescribing NSAIDS for arthritic knees should 
monitor any developing GI symptoms or the level of patient’s 
own risk for gastropathy, and be willing to add gastroprotective 
agents for the patient in order to prevent serious adverse events.
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